Kaplan Fox & Kilsheimer LLP Reminds Investors of a Securities Class Action Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and Lead Plaintiff Deadline on October 5, 2026

A securities class action has been filed against ARS Pharmaceuticals on behalf of investors who bought shares between March 9 and June 24, 2026, alleging issues related to payer-access disclosures for neffy. After ARS said no new commercial formulary additions or coverage decisions had been issued in the July 1 coverage cycle, its shares fell $2.52, or 23.9%, to $8.02 on June 25. Investors seeking lead-plaintiff status have until October 5, 2026.

Analysis

The litigation notice itself is not a new fundamental catalyst for SPRY; the economically relevant issue is whether delayed formulary wins expose a materially slower neffy launch ramp than sell-side revenue models assume. For a single-product commercial-stage biotech, payer coverage is a volume gate rather than a modest timing issue: each missed coverage cycle can shift prescriptions, gross-to-net assumptions, and cash-burn breakeven by a quarter or more. The next independently verifiable datapoints are covered-lives growth, prescription trends, net price realization, and management’s cash-runway commentary—not subsequent plaintiff-law-firm announcements.

Near term, the lead-plaintiff deadline may add retail-facing headline pressure but does not determine liability or damages. The more material 1-3 month risk is a guidance reset if formulary traction remains absent in the next cycle; that could force further multiple compression because commercialization credibility, not just near-term revenue, is being repriced. Conversely, a broad national or regional payer addition with disclosed effective dates and covered lives would weaken the bear case quickly, particularly if it supports unchanged launch guidance.

The second-order beneficiary is incumbent injectable epinephrine supply channels, where entrenched payer contracts and pharmacy substitution behavior become more valuable when a differentiated nasal alternative lacks reimbursement. However, this is unlikely to be a clean long catalyst for ALV without evidence that neffy was taking meaningful share; BAC has no actionable linkage. Consensus may overread the lawsuit as incremental downside: securities suits following a sharp disclosure-driven decline are common, while the stock’s forward path remains almost entirely a reimbursement-execution and liquidity question.

Key Decisions for Investors

• Maintain or initiate a tactical SPRY short only on failed evidence of incremental payer access over the next 1-3 months; target a further 20-30% downside if management cuts launch or cash-runway expectations, with a hard cover on a disclosed major formulary win or reaffirmed guidance backed by covered-lives data.
• Do not trade SPRY solely on the October 5 lead-plaintiff deadline. Treat it as a sentiment event; litigation settlement value is too remote and too uncertain to underwrite a fundamental position.
• For existing SPRY longs, reduce exposure or use 1-3 month downside puts if liquid. The key risk is a discontinuous guidance/cash-burn revision, for which a defined-risk hedge is preferable to relying on stop losses in a volatile small-cap biotech.
• Set an alert for the next payer-cycle update: initiate a short only if no additions coincide with weak prescription or gross-to-net metrics; conversely, consider covering shorts if management discloses meaningful covered-lives gains and maintains commercialization spending discipline.